25 省中成药集采落地 投资要点： 本报告的风险等级为中高风险。 本报告的信息均来自已公开信息，关于信息的准确性与完整性，建议投资者谨慎判断，据此入市，风险自担。 请务必阅读末页声明。 医药生物（申万）指数走势 -35% 资料来源：iFind，东莞证券研究所 相关报告 10% 医药生物 沪深300 -5% 0% 5% 10% 医药生物 沪深300 超配（维持） 医药生物行业双周报（2025/6/13-2025/6/26） 业 周 报 医药生物行业 -30% -25% -20% -15% -10% -5% 0% 5% 10% 医药生物 沪深300 -35% -30% -25% -20% -15% -10% 5% -35% -30% -25% -20% -15% -10% -5% 0% -40% -20% 0% 20% 行 业 研 究 22-03 22-05 22-07 22-09 22-11 23-01 23-03 医药生物 沪深300 -35% -30% -25% -20% -15% -10% -5% 0% 5% 10% 医药生物 沪深300 2025 年 6 月 27 日 分析师：谢雄雄 SAC 执业证书编 ...

双机配置，为区域输送人才。作为国内顶尖医疗科技企业——"微创"公司精心布局的全国核心培训基地 之一，东营市人民医院配置双机，一台直接投入临床一线，服务患者；另一台则专用于区域人才孵化， 构建起"理论+高仿真实操"的先进培训体系，为山东地区外科医师提供沉浸式操作平台。 东营市人民医院5G胸腹腔内窥镜手术系统（手术机器人）启用暨区域培训基地的授牌，是推动医院高 质量发展、满足群众高品质医疗需求的关键一步，标志着医院微创外科技术迈入了智能化、精准化的新 时代。它将在泌尿、普外、妇科、胸外科等高难度手术中发挥巨大作用，为患者带来更优质的诊疗体 验。医院将以此次胸腹腔手术机器人启用为契机，强化技术培训、规范临床应用，积极推动多学科协作 与创新，让这项技术惠及更多患者。 启用仪式上，上海微创医疗机器人（集团）股份有限公司执行董事及首席商务官刘雨为东营市人民医院 5G胸腹腔内窥镜手术系统区域培训基地授牌。上海市第一人民医院副主任医师、硕士研究生导师、泌 尿肿瘤外科治疗组组长蒋琪、上海微创医疗机器人（集团）股份有限公司执行董事及首席商务官刘雨分 别授课，介绍5G胸腹腔内窥镜手术系统（手术机器人）和5G远程技术的应用。东营市人 ...

Group 1: Core Insights - The State Administration for Market Regulation has approved the release of 43 national metrology technical standards, including 29 new and 14 updated standards, covering various fields such as digital transformation, healthcare, livelihood security, and ecological environment [1] Group 2: Digital Transformation - Two new metrology technical standards in the digital transformation field, namely the "Digital AC Energy Meter Type Evaluation Outline" and the "Digital AC Energy Meter Verification Procedure," establish measurement index evaluation standards and regulatory measures for daily use, promoting the digital transformation of the energy meter industry and ensuring fair energy transactions [2] - The implementation of the "Weighing Instrument IoT Function Measurement Technical Specification" provides a scientific, standardized, and unified testing method for the IoT function measurement in the weighing instrument industry, effectively advancing the development of digital metrology technology in domestic weighing industries [2] Group 3: Healthcare - Five new technical standards have been established in the healthcare sector to safeguard public health, including the "Transcranial Magnetic Stimulation Therapy Device Calibration Specification," which addresses the lack of a unified calibration method for such devices, filling a gap in domestic metrology standards for rehabilitation equipment [3] - The "Medical Liquid Microflow Pump Calibration Specification" standardizes the calibration work for medical liquid microflow pumps, ensuring precise control of micro-doses of medical liquids [3] - The "Blood Plasma Thawing Machine Calibration Specification" resolves issues related to inconsistent calibration methods and insufficient data comparability, providing technical support for precise temperature control during plasma thawing, which is crucial for clinical transfusion safety and maintaining the quality of blood products [3] Group 4: Accessibility - The public can access the current effective national metrology technical standards through the "National Metrology Technical Standards Full Text Public System" for free [4]

导读： 两批招标总预算达2910万元，旨在为1584台实验设备提供维修保养服务。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 近期，中国食品药品检定研究院公布了生物安全柜等设备维保服务及2025-2026年实验设备 维保服务（第一批）两项公开招标公告。这两批招标总预算达2910万元，旨在为1584台实验 设备提供维修保养服务。 预算金额：180.000000 万元（人民币） 采购需求： 项目编号：HCZB-2025-ZB0732 项目名称：中国食品药品检定研究院2025-2026年实验设备维保服务第一批采购项目 预算金额：2730.000000 万元（人民币） 最高限价（如有）：2730.000000 万元（人民币） 采购需求： | | 分包预算金额 | | | --- | --- | --- | | 包号 | | 采购需求 | | | （万元） | | | 第一包 | 559 | 为采购人的91台安捷伦设备仪器提供维修 | | | | 保养服务。 | | 第二包 | 339 | 为采购人的50台赛默飞设备仪器提供维修 | | | | ...

方才趟过销量低迷期，如今又临价格困境。 这波集采降价不分品牌、种类、品次，中低端降幅尤为惨烈。以县域医共体设备更新为例，200万一台的1.5T磁共振，100万一台的64排 CT，不到50万一台的全身超声，将医疗设备的价格拉低到了一个过往难以想象的价格。 此外，采购方普遍要求厂商提供5年设备维保，本已微薄的利润，又被进一步压缩，或是直接转负。 站在支付方的角度，医药、试剂、耗材均已实行多年集采，设备作为开销的重要组成，没有理由脱离集采。 国产设备厂商亦有其心酸：摆脱跨国企业统治力不过短短数年，还未尝足甜头就得卷起价格。 凛冬之后又是一个凛冬，医疗设备未来何去何从？ | 序号 | 地区 | 采购设备 | 中标品牌 | 设备名称 | | | 数量(台)集采单价(元)动(按2024年后采购 总价(元) | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 25 | 1.5T磁共振 | 东软医疗 | NeuMR Rena G | 4 | 262万 | 65.0%-73.7% | 1048万 | | | | | | | 1 | | | | | ...

文 | 新浪财经 刘丽丽 6月24日，在世界经济论坛2025年新领军者年会期间，"AI时代的企业家精神"——夏季达 沃斯贵州茅台·新浪财经之夜在天津举办，共同探讨AI时代企业家精神的内涵、价值与实践 路径。 联合国前副秘书长金垣洙，华大集团首席执行官、执行董事尹烨，IBM大中华区董事长、总 经理陈旭东，浙江强脑科技有限公司合伙人何熙昱锦，工业富联董事长郑弘孟，赛力斯集团 副总裁康波等重量级嘉宾分享了真知灼见。 新浪财经邓庆旭 AI时代的企业家精神 是学会"驯化"算法 新浪财经CEO邓庆旭 新浪财经CEO邓庆旭在致辞中表示，AI时代的企业家精神，不是被算法驯化，而是要学 会"驯化"算法；不是成为数据的附庸，而是要成为运用数据创造独特价值的"首席人性 官"。 他强调，"利用工具，更要超越工具：让AI成为我们洞察世界、服务用户的强大助手，但决 策的罗盘，永远握在企业家基于价值观和愿景的判断手中。敬畏数据，更要关怀人心：在数 据洪流中，始终保持对人性的温度、对社会的责任、对可持续发展的担当。" 联合国前副秘书长金垣洙 应创建跨国人工智能机构 防止技术滥用 联合国前副秘书长金垣洙 联合国前副秘书长金垣洙指出，十年前，当 ...

Core Insights - The article emphasizes that going global is a key strategy for companies to enhance competitiveness and achieve high-quality development in the context of accelerated globalization and industrial chain restructuring [1] Group 1: Growth of Overseas Business - In 2024, the number of A-share listed companies with overseas operations exceeds 3,560, accounting for 66.37% of the total, both figures reaching historical highs [2] - A-share companies' overseas business revenue surpasses 10 trillion yuan, a 2.8 times increase compared to ten years ago; overseas revenue accounts for 14.28% of total revenue, up 4.65 percentage points from a decade ago [2] - The gross profit from overseas business reaches 1.63 trillion yuan, an 8.33 times increase over ten years, with its share of total gross profit rising to 14.71%, marking the first time gross profit from overseas exceeds revenue from overseas [2] Group 2: Factors Driving Internationalization - The continuous development of overseas business reflects substantial breakthroughs in internationalization strategies, driven by factors such as domestic market slowdown, opportunities in emerging markets, enhanced competitiveness in key sectors, and supportive national policies [3][5] - Emerging markets like Southeast Asia, the Middle East, Latin America, and Africa present strong economic growth and demand, providing vast opportunities for Chinese companies [3] - National strategies like the "Belt and Road" initiative and "dual circulation" encourage companies to leverage domestic and international resources to enhance competitiveness [3] Group 3: Industry-Specific Trends - The electronics industry has become the largest contributor to overseas revenue among A-share companies, surpassing the oil and petrochemical sector, which has seen a significant decline in its share [4] - In 2024, the electronics sector's overseas revenue reaches 1.39 trillion yuan, accounting for 13.58% of A-share revenue, while the automotive sector's overseas revenue rises to 9.88% [4] - Traditional industries like oil and petrochemicals have seen a decline in their overseas revenue share, indicating a shift in comparative advantages as global industrial structures evolve [4] Group 4: Transformations in Overseas Operations - The data indicates a fourfold transformation in overseas business: a shift in industrial competitiveness, the emergence of new growth drivers, changes in global demand structures, and the effectiveness of national strategic guidance [5] - Companies are transitioning from merely exporting products to establishing brand presence and deepening market integration, reflecting a higher stage of internationalization [5] Group 5: Successful Case Studies - Leading companies like BYD and Luxshare Precision have successfully expanded their global market presence, significantly enhancing their international competitiveness and brand influence [6][8] - BYD's overseas revenue has grown from 7.46 billion yuan in 2014 to 221.88 billion yuan in 2024, marking a 28.7 times increase, while Luxshare Precision's overseas revenue reaches 235.47 billion yuan, a 37.2 times increase [8][7] Group 6: Evolving Business Models - Chinese companies are moving beyond traditional export models to a more diversified approach that emphasizes technology leadership, ecological collaboration, and compliance adaptability [9][10] - Companies like CATL and Mindray are establishing regional technical standards and licensing technologies, reflecting a shift from being mere participants to defining international standards [10]

Core Insights - Nearly 75% of Chinese people face sub-health issues, highlighting the urgent need for effective health management tools [1] - Ant Group launched the AI health application "AQ" to address healthcare needs, offering over a hundred AI features including health education, consultation, report interpretation, and health records [3][4] Group 1: Product Features - AQ is designed with three main characteristics: more professional Q&A, comprehensive services, and personalized health understanding [4] - The application can guide users in accurately describing symptoms and provide tailored health advice, including the ability to analyze images for skin conditions [4] - AQ collaborates with health management devices and wearable technology to offer personalized health recommendations based on user data [4] Group 2: Professional Involvement - The development of AQ is supported by a robust technical foundation and the involvement of over a thousand medical professionals [5] - The AI avatars in AQ can significantly increase patient service capacity, with one doctor able to assist over 110,000 patients in a single day [5] - Experts believe that products like AQ can help bridge resource gaps in healthcare and improve resource allocation for chronic disease management [5]

Core Insights - Ant Group launched an AI health application named "AQ" on June 26, which offers various AI functionalities including health education, consultation, report interpretation, and health records management [1] - The application connects over 5,000 public hospitals and nearly 1 million doctors available for appointments or online consultations [1] - The new app is an independent version of the "AI Health Manager" that was launched on Alipay last September, which has served over 70 million users [1] Group 1 - AQ features three main characteristics: more professional Q&A, comprehensive services, and personalized health understanding [1] - The app provides cloud companion services from over 200 hospitals, assisting users during offline medical visits [1] - A team of nearly 200 top-tier doctors, led by experts from the Chinese Academy of Engineering, is available on AQ to answer user queries in real-time [1] Group 2 - AQ collaborates with health management device companies like Yuyue and SanNuow, and integrates with wearable devices from brands such as Vivo, Huawei, and Apple to offer personalized health advice based on user data [1] - The technical engine of AQ is powered by Ant Group's medical model, which has learned from over a trillion tokens of specialized medical data and supports multimodal interactions including images, voice, and video [1] - Ant Group aims to enhance accessibility to healthcare and promote public health by continuously expanding partnerships with more stakeholders in the healthcare sector [2]

Core Insights - The Chinese pharmaceutical industry is undergoing a new round of deep integration driven by policy guidance and market demand [1][2] - China National Pharmaceutical Group (Sinopharm) has announced acquisitions of two listed companies, Plasmed Biopharma and Shandong Pharmaceutical Glass, exemplifying recent M&A activity in the sector [1][2] Industry Trends - State-owned enterprises are becoming the main players in the M&A market, significantly altering the competitive landscape with their strong financial capabilities and resource integration skills [2][3] - Major industry players like Sinopharm, China Resources Pharmaceutical Group, and China General Technology Group are building competitive advantages across the entire supply chain through horizontal and vertical integration [2][3] Company Strategies - Sinopharm is focusing on strengthening its acquisition and integration strategies, aiming to enhance its market position in the health sector [3][4] - The acquisition of Plasmed Biopharma and Shandong Pharmaceutical Glass will allow Sinopharm to consolidate its supply chain, ensuring the safety and stability of the biopharmaceutical supply chain [4][6] Market Dynamics - The blood products sector is particularly strategic due to the limited number of licenses available since 2001, making existing licenses and plasma stations highly valuable [4][5] - Following the acquisition, Sinopharm's combined plasma collection volume from its subsidiaries is expected to exceed 4,181 tons, accounting for 31.2% of the national total [4][5] Financial Performance - Shandong Pharmaceutical Glass, as a leading player in the pharmaceutical glass sector, reported a revenue of 5.125 billion and a net profit of 943 million in 2024, marking 12 consecutive years of growth [5][6] Future Outlook - The M&A trend in the pharmaceutical industry is expected to evolve towards integrated supply chain acquisitions, cross-border expansions, and innovative ecosystem constructions [7]